The UK biotech has announced an investment agreement with Japan-based pharmaceutical company Miyarisan to help scale and manufacture their oral therapeutics pipeline.

Nottingham, UK- 3rd January 2023- FOR IMMEDIATE RELEASE

Miyarisan currently manufacture the probiotic bacterial strain MIYARI 588 for Asian and European markets, and bring extensive Clostridium bacterial spore manufacturing and formulation expertise, along with fermentation process development to the table. Combined with CHAIN’s engineering biology expertise, the two companies plan to repurpose a proven Clostridium probiotic species into a therapeutic, co-developing and manufacturing novel oral treatments targeting infection and cancer.

CHAIN’s Clostridium Assisted Drug Delivery (CADD) platform has broad therapeutic applications which, with strategic investment and support from Miyarisan, can be used to develop drug candidates addressing a range of immune-oncological and infective targets.

CHAIN has also recently partnered with the University of Oxford, focusing on the development of a superior oral vaccine for Human Rotavirus (HRV). HRV is the leading cause of Childhood Diarrhoeal Diseases (CDDs) in low-income countries, affecting over 1.7 billion children every year and resulting in over 500,000 deaths. CHAIN’s oral vaccine being developed through the project aims to subvert the vaccine efficacy gap and combat vaccine inequality, utilising the investment and collaboration from Miyarisan to provide a route to scale-up and manufacture.

CHAIN CEO Dr. Matthew Duchars said:

“CHAIN is excited to have Miyarisan as a strategic investor. Miyarisan have a wealth of experience in commercial scale manufacturing which is highly synergistic with CHAIN’s experience in the genetic engineering of probiotic strains. By applying CHAIN’s unique CADD system to new disease targets and combining that with Miyarisan’s strength in manufacturing, the two companies can accelerate the development of medicines to help prevent and treat target diseases.”

Masayuki UCHIDA, President of Miyarisan Pharmaceutical added:

“Miyarisan Pharmaceutical’s is pleased to announce an investment in CHAIN Biotechnology. The two companies share a mutual interest in developing products that enhance the microbiome to improve health. CHAIN has combined innovative genetic engineering with microbiome technology using their “CADD” system, and has the potential to broaden microbiome technologies for use against specific disease targets. The combination of CHAIN’s high-quality genetic engineering science, coupled with Miyarisan’s experience in manufacture of microbiome enhancing live biotherapeutic products will create an opportunity to benefit patients, through the development of new and improved medicines.”

About Miyarisan Pharmaceutical

Miyarisan is a pharmaceutical company based in Japan, with a corporate office in Tokyo and manufacturing and development plants in Nagano and Saitama.

Miyarisan manufacture and market their probiotic C.butyricum strain MIYARI 588 in Japan, where it is commercially available to treat both non-antimicrobial induced diarrhoea and antimicrobial associated diarrhoea in humans. The strain was discovered in by Dr. Miyairi in 1933 at the department of Hygiene at Chiba Medical College, and since its first commercial production in 1940, it has developed into an efficacious treatment for colitis and gastroenteritis.

Miyarisan also manufacture over-the-counter probiotics, which are available in Japan and Korea, and were approved by the European Commission as a ‘novel food’ in 2014 for EU markets. Miyarisan’s MIYARI 588-based animal feed additive, MIYA-GOLD, has been shown to increase growth performance without modifying the commensal microbiome when used as a probiotic and is available globally.

For more information, please visit

About CHAIN Biotech

CHAIN Biotechnology is a microbiome therapeutics company based at MediCity Nottingham with a head office in Marlow. CHAIN develops oral vaccines and immuno-therapies targeting the lower gastrointestinal tract with several therapeutic candidates in pre-clinical development.

CHAIN’s Clostridium Assisted Drug Development platform (CADD) technology is based on a single, but highly effective, Clostridium bacterial strain that is engineered to deliver a specific therapeutic modality, whilst also secreting metabolites that play key roles in gut and immune system homeostasis. The engineered strains produce the therapeutics in situ during growth in the lower gastrointestinal tract, impacting on the systemic and mucosal immune system.

The CADD platform supports oral drug delivery that is targeted and controllable. In addition, our live biotherapeutics can be manufactured easily and cost-effectively and are highly stable (no cold chain logistics). The technology overcomes many of the challenges associated with drug delivery and vaccination.

For more information, please visit:

CHAIN announces the appointment of Dr Matthew Duchars as Chief Executive from the 1st of August 2022

Nottingham, UK- 22nd of July 2022- FOR IMMEDIATE RELEASE

CHAIN Biotechnology has strengthened its senior management team through the appointment of Dr Matthew Duchars.

Matthew is an experienced leader in vaccine development and manufacture with senior management roles at the Vaccine Manufacturing and Innovation Centre, Oxford (CEO), the Sabin Vaccine institute, Washington DC, USA (Senior Vice President, R&D) and with Emergent Biosolutions, Gaithersburg, MD, USA (Vice President, Product Development).  

CHAIN Biotech has developed an innovative CADDTM platform which is based on living gut bacteria that form part of the microbiome. The bacteria produce functional molecules in the lower gastrointestinal tract where they have a positive impact on the gut microbiome and mucosal health. Engineering biology is used to add additional therapeutic functionality through the expression of specific antigenic peptides, which makes the CADDTM platform ideally suited for oral vaccines.

Matthew will replace CHAIN’s founder Dr Edward Green as Chief Executive with a focus on further developing the CADDTM platform for oral vaccination. Edward will remain on the Board, and act as Chief Scientific Advisor.

Dr Matthew Duchars said:

“I am excited to join the CHAIN team. I am greatly impressed by their expertise and highly innovative CADDTM platform technology with the potential to develop effective oral vaccines. The company has done a great job securing several strategic partnerships that bring both credibility and help de-risk drug development and manufacture.”  

Dr Nel Moore, Chair of CHAIN Biotech, said:  

“We are delighted to welcome Matthew to CHAIN’s leadership team. Matthew brings a wealth of experience in vaccine development and manufacture that complements our strain engineering and microbiology skills. I look forward to working closely with Matthew to develop our technology for oral vaccine applications, bringing benefit to patients and building shareholder value.”


For more information please contact:

Edward Green, CHAIN Biotech

T: +44 (0)775 3610798 | E:

CHAIN announces a new collaboration with clinical researchers at the University of Oxford to develop superior oral vaccines for infectious diseases

Marlow, UK- 22nd of June 2022- FOR IMMEDIATE RELEASE

CHAIN Biotechnology and the University of Oxford plan to collaborate on a two-year project to develop a new type of vaccine to immunise against human rotavirus (HRV) infection. Ultimately, the aim is to prevent Childhood Diarrhoeal Disease in malnourished children and transform the lives of millions of families across the world.

Childhood Diarrhoeal Disease (CDD) is a global health problem affecting over 1.7 billion children every year and resulting in over 500,000 deaths, mainly in low-income countries. The most common cause of CDD is infection with human rotavirus (HRV). Oral vaccines that protect against HRV infection are available but relatively expensive, and difficult to transport and administer in remote areas as they need to be kept cold. Also, they are largely ineffective in undernourished children.

We aim to develop a superior oral vaccine for HRV that is simple, inexpensive, highly effective and overcomes oral vaccine challenges associated with antigen preservation, antigen delivery and immune stimulation. Our goal is to subvert the vaccine efficacy gap in low-income countries and combat vaccine inequality.

CHAIN Biotech has developed an innovative CADDTM platform for oral drug delivery, based on living gutbacteria with a long, safe history of use in humans and engineered to deliver specific therapeutic cargo to the lower gastrointestinal tract. The bacteria are delivered orally, in spore form, and travel intact through the stomach and small intestine until they reach the colon where they germinate. The bacterial cells then grow and produce candidate molecules impacting on the gut mucosa. The CADDTM platform can be used for oral vaccination through the expression of specific antigenic peptides.

In this project, CHAIN will engineer Clostridium to secrete antigenic peptides designed to provoke an immune response against HRV. The University will undertake pre-clinical evaluation. This work will be led by Dr Kelsey Jones, a Senior Clinical Research Fellow at the Kennedy Institute of Rheumatology, University of Oxford, and an Honorary Consultant Paediatric Gastroenterologist at Great Ormond Street Hospital. Dr Jones investigates the association between malnutrition, immunology, and poverty with pioneering research into the effect of undernutrition on the innate immune system in the gut.

The project is supported by a grant from Innovate UK’s Biomedical Catalyst programme. The Assessors felt ‘the project has good potential with a favourable risk-reward profile, addresses high unmet clinical need and that the technical solution was highly innovative. Overall, CHAIN’s oral vaccine platform was deemed very attractive for public finding adding to the UK’s leadership in the vaccine field.’

Dr Edward Green, Chief Executive of CHAIN Biotech, said:  

‘We are really excited about our new project with the Kennedy Institute and the potential to build on this collaboration to validate our oral vaccine candidates. The University has world class expertise and facilities that should accelerate the development of our novel microbiome therapeutics for a broad range of clinical indications including oncology.’

Professor Fiona Powrie FRS, Professor of Musculoskeletal Sciences and Director of the Kennedy Institute of Rheumatology, added:

‘We are delighted to partner with CHAIN Biotech in developing this innovative mucosal vaccine platform. The ability to use the CADD system to target delivery of antigens and other molecules to specific regions of the gastrointestinal tract has significant translational potential.’


For more information please contact:

Edward Green, CHAIN Biotech

T: +44 (0)775 3610798 | E:

Notes to Editor

About the Kennedy Institute

The Kennedy Institute of Rheumatology at the University of Oxford is a world-leading medical research centre.  Discovery research drives development of transformative therapies for chronic inflammatory and degenerative disease. Directed by Professor Fiona Powrie FRS, the Kennedy Institute has over 25 research groups working in the areas of immunity and microbiome, inflammation biology and tissue re-modelling and repair. Investigators at the Institute take a multidisciplinary approach incorporating molecular and cellular biology with analysis of disease models and interrogation of patient tissue samples.

For more information, please visit: Homepage — The Kennedy Institute of Rheumatology (

Following successful patent applications in the EU and US, CHAIN have extended their patent territories and claimed delivery of β-hydroxy butyrate (β-HB) to the gastrointestinal (GI) tract in Japan. The patent family (publication number: WO2018055388) ‘Compositions and uses thereof for treating inflammatory diseases and probiotic compositions’ covers genetically engineered bacterial strains to express β-HB in the lower GI tract.

β-HB has gained recent attention as a powerful therapeutic targeting a variety of GI diseases, including inflammatory bowel disease and colorectal cancer. However, traditional delivery methods present overloading issues surrounding carrier substances such as salts or esters; a factor which can be bypassed by direct delivery of β-HB to the lower GI tract. CHAIN’s novel CADD™ platform bacterial strain is engineered to secrete β-HB on arrival in the lower GI tract where it can elicit its therapeutic effects, removing the need for additional compounds.

A recent Nature publication has highlighted a possible role of β-HB in the suppression of colorectal cancer by modulating gene expression and inhibiting cell proliferation. The research presents promising future roles of β-HB as an oncological therapeutic.

CHAIN hopes to further extend the patent in the future, to maximise the impact of therapeutic β-HB in treating GI disease.